Fig. 2. Positron emission tomography (PET) imaging with [18F]flumazenil in adults with autism spectrum disorder (ASD) and typically developing (TD) individuals.
a Group-mean parametric maps derived from PET data in standard MNI space. Color bar represents non-displaceable binding potential (BPND) of [18F]flumazenil. Mean parametric maps do not differ significantly between groups. b Group-mean BPND of [18F]flumazenil in the thalami and left DLPFC, as detected by PET. Error bars represent ±1 SEM. Mean BPND in these regions of interest do not differ significantly between groups.